Posts

Bosutinib FDA approved for the treatment of patients with newly-diagnosed chronic phase Ph+ CML

On 19 December 2017, the FDA granted accelerated approval to bosutinib (Bosulif®, Pfizer) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML).